2Garattini L, Cornago D, De Compadri P. Pricing andreimbursement of in -patent drugs in seven Europeancountries: A comparative analysis [J]. Health Policy,2007, 82 (3): 330-9.
6Garattini L,Cornago D,De Compadri P.Pricing and reimbursement of in-patent drugs in seven European countries:A compaative analysis[J].Health Policy,2007,82(3):330-339.
7Schneeweiss S,Sch(o)ffski O,Selke GW.What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?[J].Health Policy,1998,44(3):253-260.
8BLOOM N,REENEN J.Regulating drug prices:where do We go from here?[J].Fiscal Studies,1998,19(3):321-342.
9Birkett DJ,Mitchell AS,McManus P.A cost-Effectiveness approach to drug subsidy and pricing in Australia[J].Health Aff(Millwood),2001,20(3):104-114.
10Schulenburg JM, Gramf VD.The Geman health care system at the crossroads[S] .Health Economics, 1994,3:301.
